Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.

After adjustment, compared to individuals on an INSTI, those on a PI/b or an NNRTI had lower odds of achieving a CD4 count ≥750 cells/μL (aOR 0.84 [0.70–1.01], p = 0.06 or 0.62 [0.52–0.72], P <0.001 respectively; Fig 4B ), although this did not reach statistical significance for the PI/b group.

also in 111,027 other papers